Department of Microbiology, Tumor and Cell biology (MTC), Biomedicum, Karolinska Institutet, Stockholm, Sweden.
Department of Infectious Diseases, Visby County Hospital, Visby, Sweden.
J Intern Med. 2022 Aug;292(2):350-364. doi: 10.1111/joim.13488. Epub 2022 Apr 3.
Bacterial meningitis (BM) is a rare but severe infection. Few population-based studies have characterised BM episodes and sequelae over long periods.
This was a population-based observational cohort study with national coverage, using data on aetiological pathogens, sex, premorbid conditions, steroid pretreatment, severe sequelae and birth, death and diagnosis dates collected from 10,339 patients with BM reported to the National Board of Health and Welfare in Sweden between 1964 and 2014.
During the 50-year study period, the incidence of BM decreased in young children, but not in the elderly. The most common cause of BM was pneumococci (34%), followed by Haemophilus influenzae (26%), and meningococci (18%), mainly community acquired. Premorbid conditions were found in 20%. After the H. influenzae type b vaccine was introduced in 1993, the BM incidence decreased by 36%. Following pneumococcal conjugated vaccine introduction in 2009, the incidence and 30-day mortality from pneumococcal meningitis decreased by 64% and 100%, respectively, in previously healthy children, and the 30-day mortality decreased by 64% among comorbid adults. The BM incidence in immunosuppressed patients increased by 3% annually post vaccine introduction. The 30-day mortality was 3% in children and 14% in adults, and the rate of severe sequelae was 44%. On average, patients lost 11 years of healthy life due to BM.
The introduction of conjugated vaccines into the childhood vaccination program has reduced the incidence of BM in young children, but not in adults. Post vaccine introduction, patients present with more premorbid conditions and other bacterial causes of BM, emphasising the need for a correct diagnosis when treating these infections.
细菌性脑膜炎(BM)是一种罕见但严重的感染。很少有基于人群的研究能够长期描述 BM 发作和后遗症。
这是一项具有全国覆盖范围的基于人群的观察性队列研究,使用了从瑞典国家卫生局和福利局在 1964 年至 2014 年间报告的 10339 名 BM 患者的病因病原体、性别、前驱疾病、类固醇预处理、严重后遗症和出生、死亡和诊断日期等数据进行研究。
在 50 年的研究期间,儿童的 BM 发病率下降,但老年人的发病率没有下降。BM 最常见的病因是肺炎球菌(34%),其次是流感嗜血杆菌(26%)和脑膜炎球菌(18%),主要是社区获得性的。20%的患者有前驱疾病。1993 年乙型流感嗜血杆菌疫苗问世后,BM 的发病率下降了 36%。2009 年引入肺炎球菌结合疫苗后,原本健康的儿童的肺炎球菌性脑膜炎发病率和 30 天死亡率分别下降了 64%和 100%,合并症成年人的 30 天死亡率下降了 64%。疫苗接种后,免疫抑制患者的 BM 发病率每年增加 3%。儿童的 30 天死亡率为 3%,成年人的死亡率为 14%,严重后遗症的发生率为 44%。平均而言,BM 使患者失去了 11 年的健康寿命。
将结合疫苗引入儿童免疫接种计划已经降低了儿童的 BM 发病率,但对成年人没有影响。疫苗接种后,患者出现更多的前驱疾病和其他细菌性 BM 病因,这强调了在治疗这些感染时需要正确诊断。